Budesonide

Producers shown on SFDA

(Record date:14/10/2021）

Producers shown on EP

(Quoted from EP website；record date:14/10/2021）

Producer:Hubei Gedian Humanwell Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical enterprise invested and controlled by humanwell Pharmaceutical Group Co., Ltd. specializing in the R & D, production and sales of fertility regulating drugs and steroidal APIs.The company covers an area of 80000 square meters and a construction area of 15000 square meters.

Up to now, 6 workshops of the company have passed the national GMP certification; The new steroid hormone API workshop invested and built has passed the FDA certification.

Staff size:50-99 persons

Registered capital:RMB 128.255 million

Producer:Tianjin Tianyao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianjin Jinyao Group Co., Ltd., is the first API production unit in Tianjin that has all passed the national GMP certification. It is the largest scientific research, production and export base of steroid corticosteroids in Asia. The company mainly produces more than 40 varieties of corticosteroid raw materials, cardiovascular and cerebrovascular raw materials, analgesic raw materials and preparation drugs, of which many products have passed the certification of FDA and European Pharmacopoeia Committee, and become a qualified supplier of Pfizer and other large multinational companies. The company's leading product dexamethasone (corticosteroid drugs) series technology and product quality have reached the international advanced level. Taking advantage of low cost and service advantages, the company has occupied the Asian market of dexamethasone and opened the European and American markets; The company's annual production capacity of corticosteroid APIs has reached more than 200 tons.
Staff size:About 3000 persons

Registered capital:RMB 1 billion 101 million

Producer:Lunan Better Pharmaceutical Co., Ltd., a holding subsidiary of Lunan Pharmaceutical Group Co., Ltd., was established in 2003. The company produces 12 formulations including western medicine tablets, injections, sustained release tablets, large infusion, spray, capsule, granule, eye drops and so on. It mainly consists of Lunan Xin Kang tablets, Lunan Xin Kang sustained-release tablets, Nonan Bate tablets, Isosorbide Mononitrate Injection, Lunan Li Kang, Omeprazole Enteric-coated Tablets, cetirizine hydrochloride, sotalol hydrochloride and anisetam granules. 22 products, including aximus capsule, isoflurane anesthetic, salmeterol aerosol and ciprofloxacin hydrochloride eye drops, have all passed the national GMP verification in the production workshop.

Staff size:4000-4999 persons

Registered capital:RMB 115 million

Producer:Shanghai Sine Promod Pharmaceutical Co., Ltd. covers a total area of 100000 square meters, including 17000 square meters of building area and more than 40000 square meters of green and forest belt area.

The company has five workshops: Traditional Chinese medicine extraction workshop, tablet and capsule workshop, two chemical synthesis workshops (budesonide, moclobemide) and antibiotic workshop (cephalosporins). All five workshops have passed GMP certification (traditional Chinese medicine extraction workshop took the lead in passing GMP certification in Shanghai), with an annual production capacity of 1 billion tablets and an annual output of 400 million Ginkgo biloba preparations.

Staff size:100-199 persons

Registered capital:RMB 50 million

Producer:Lianyungang Runzhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary and API production base of Zhengda Tianqing Pharmaceutical Group, was established in 2010, covering an area of 206 mu. In 2012, it was recognized as a high-tech enterprise, mainly engaged in the R & D, production and sales of various chemical APIs.

At present, the company has 7 product production workshops, 4 pilot workshops for new products, 1 product development center, and 2 drug inspection centers, power workshops and warehouses. There are 52 products approved for listing in China, of which 16 are listed as high-tech products in Jiangsu Province, involving liver disease, tumor, cardiovascular, respiratory and other fields, with an annual production capacity of more than 100 tons.

With the continuous increase of product types and production scale, the economic benefits of the company have also increased year by year. In 2020, the sales revenue will reach 3.5 billion yuan, including 10 API products such as arotinib hydrochloride, magnesium isoglycyrrhizinate and Diammonium Glycyrrhizinate, forming a "product group with sales of more than 100 million". The company has passed FDA certification for "zero defect" twice, and 14 products passed GMP on-site inspection in 2020, indicating that the company's quality management is at a high level in the industry.

Staff size:1000-1999 persons

Registered capital:RMB 103 million 528 thousand and 805

Producer:Astrazeneca Pharmaceutical Co., Ltd. is a global pharmaceutical company, founded in 1913, headquartered in London, UK and R & D headquarters in Sweden. There are 17 R & D institutions in 8 countries, with 13000 employees engaged in work related to new drug R & D.

Staff size:700-799 persons

Registered capital:USD 91.2 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978